UBE3A Antisense Oligonucleotides for Targeted Gene Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders associated with UBE3A gene copy number variations, such as Dup15q syndrome, are inadequate in addressing symptoms like seizures, hypotonia, motor delays, and autism spectrum disorders.
Innovation Solution
The use of antisense oligonucleotides (ASOs) that are complementary to UBE3A transcripts to inhibit protein expression by hybridizing with UBE3A pre-mRNA or mRNA, recruiting RNaseH for cleavage and preventing translation into protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to knock down UBE3A expression, then symptoms of Dup15q syndrome are alleviated, but the complexity of the treatment increases
Solution Approach 1:
The patent employs antisense oligonucleotides as intermediary molecules that mediate between the therapeutic goal (UBE3A knockdown) and the biological target (UBE3A mRNA). These ASOs hybridize to specific sequences in UBE3A transcripts and recruit RNase H to cleave the target RNA, providing a mechanistic bridge that achieves symptom alleviation through targeted gene silencing while maintaining a relatively simple administration approach
Solution Approach 2:
The patent replaces conventional mechanical or chemical approaches to symptom management with a molecular biology-based mechanism. Instead of using traditional drugs that modulate protein function, the invention uses antisense oligonucleotides that directly interfere with gene expression at the RNA level, substituting a biochemical mechanism for more complex pharmacological interventions
2Reliability
If ASOs are designed to hybridize to UBE3A transcripts, then protein expression is inhibited, but the manufacturing precision requirements increase
Solution Approach 1:
The patent applies local quality by designing ASOs with specific sequence characteristics tailored to different regions of the UBE3A transcript. The oligonucleotides are engineered with particular base compositions, lengths, and modifications at specific positions to optimize hybridization to target sequences while minimizing off-target effects, allowing different ASOs to have specialized properties suited to their specific binding sites
Solution Approach 2:
The patent utilizes parameter changes by systematically varying ASO characteristics such as length (15-30 nucleotides), nucleotide composition, chemical modifications (phosphorothioate backbone, 2'-O-methyl RNA wings), and sequence identity (75-100% complementarity) to optimize both manufacturing feasibility and knockdown efficacy. These parameter adjustments allow for standardized production protocols while maintaining high precision requirements for the active sequence regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASOs effectively reduce UBE3A protein expression, thereby alleviating symptoms of Dup15q syndrome, including seizures, hypotonia, and autism spectrum disorders, through targeted gene knockdown.
Implementation Method 1
The ASO hybridizes to a complementary target in a transcript from a UBE3A gene
Implementation Method 2
When the antisense oligonucleotide (ASO) hybridizes to its target RNA, it forms a double-stranded ASO:RNA duplex that recruits an enzyme (RNaseH) that degrades a portion of the double-stranded duplex
Data Source
AI summary
The invention provides compositions useful to knock down overexpression of UBE3A and treat conditions associated with Dup15q syndrome. The compositions include antisense oligonucleotides, preferably short oligonucleotides that are complementary to, and hybridize to, UBE3A transcripts in vivo. The ASOs prevent or inhibit successful translation of UBE3A mRNA into protein. Specifically, preferred embodiments include anti-UBE3A gapmers—oligos that include a central DNA portion flanked by RNA wings. When the gapmer hybridizes to UBE3A pre-mRNA or mRNA, the duplex hybrid recruits RNaseH, which cleaves, or digests, the UBE3A pre-mRNA or mRNA, preventing expression of the UBE3A protein. Because the ASOs prevent expression of the UBE3A protein, treatment with a composition including ASOs of the disclosure may be effective to knock down overexpression of UBE3A.